Risk factors for antipsychotic medication non-adherence behaviors and attitudes in adult-onset psychosis

Schizophrenia Research

Volumn 174, Issue 1-3, 2016, Pages 144-149

  Hui, Christy Lai Ming ^a   Poon, Venessa Wing Yan ^a   Ko, Wai Tung ^a   Miao, Ho Yee ^a   Chang, Wing Chung ^a,b   Lee, Edwin Ho Ming ^a   Chan, Sherry Kit Wa ^a,b   Lin, Jingxia ^a   Chen, Eric Yu Hai ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adherence; Antipsychotics; First episode; Predictors; Psychosis

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; FLUPENTIXOL; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; BEHAVIOR ASSESSMENT; COGNITIVE DEFECT; FEMALE; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; RATING SCALE; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ATTITUDE TO HEALTH; CONTROLLED STUDY; MEDICATION COMPLIANCE; ODDS RATIO; ONSET AGE; PROGNOSIS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; COGNITIVE DYSFUNCTION; FEMALE; HONG KONG; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PSYCHOTIC DISORDERS; RISK FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 84961901442     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.03.026     Document Type: Article

References (47)

1. Abdel-Baki A., Ouellet-Plamondon C., Malla A. Pharmacotherapy challenges in patients with first-episode psychosis. J. Affect. Disord. 2012, 138:S3-S14.
2. Acosta F.J., Hernández J.L., Pereira J., Herrera J., Rodríguez C.J. Medication adherence in schizophrenia. World J. Psychiatry 2012, 2:74-82.
3. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154(5):672-676.
4. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982, 8(3):470.
5. Caseiro O., Pérez-Iglesias R., Mata I., Martínez-Garcia O., Pelayo-Terán J.M., Tabares-Seisdedos R., de la Foz V.O.-G., Vázquez-Barquero J.L., Crespo-Facorro B. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J. Psychiatr. Res. 2012, 46(8):1099-1105.
6. Chen E.Y.-H., Hui C.L.-M., Dunn E.L.-W., Miao M.Y.-K., Yeung W.-S., Wong C.-K., Chan W.-F., Tang W.-N. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr. Res. 2005, 77(1):99-104.
7. Coldham E., Addington J., Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr. Scand. 2002, 106(4):286-290.
8. Cooper C., Bebbington P., King M., Brugha T., Meltzer H., Bhugra D., Jenkins R. Why people do not take their psychotropic drugs as prescribed: Results of the 2000 National Psychiatric Morbidity Survey. Arch. Psychiatr. Scand. 2007, 116(1):47-53.
9. Ekman M., Granstrom O., Omerov S., Jacob J., Landen M. The societal cost of schizophrenia in sweden. J. Ment. Health Policy Econ. 2013, 16(1):13-25.
10. Farooq S., Naeem F. Tackling nonadherence in psychiatric disorders: current opinion. Neuropsychiatr. Dis. Treat. 2014, 10:1069.
11. Fialko L., Garety P.A., Kuipers E., Dunn G., Bebbington P.E., Fowler D., Freeman D. A large-scale validation study of the medication adherence rating scale (MARS). Schizophr. Res. 2008, 100(1-3):53-59.
12. Foerster A., Lewis S., Owen M., Murray R. Pre-morbid adjustment and personality in psychosis. Effects of sex and diagnosis. Br. J. Psychiatry 1991, 158(2):171-176.
13. Goldman H., Skodol A., Lave T. Revising axis V for DSM-IV: a review of measures of social functioning. Am. J. Psychiatry 1992, 149:1148-1156.
14. Goodman S.H., Sewell D.R., Cooley E.L., Leavitt N. Assessing levels of adaptive functioning: the role functioning scale. Community Ment. Health J. 1993, 29(2):119-131.
15. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.
16. Haynes R.B., McDonald H., Garg A., Montague P. Interventions for helping patients to follow prescriptions for medications. The Cochrane Library 2002.
17. Higashi K., Medic G., Littlewood K.J., Diez T., Granström O., De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther. Adv. Psychopharmacol. 2013, 3(4):200-218.
18. Hofer A., Kemmler G., Eder U., Honeder M., Hummer M., Fleischhacker W.W. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J. Clin. Psychiatry 2002, 63(1):49-53.
19. Hon A. Factors influencing the adherence of antipsychotic medication (Aripiprazole) in first-episode psychosis: findings from a grounded theory study. J. Psychiatr. Ment. Health Nurs. 2012, 19(4):354-361.
20. Hong Kong Psychological Society The Wechsler Adult Intelligence Scale-Revised (Cantonese version) 1989, Hong Kong Psychological Society, Hong Kong.
21. Hong Kong Psychological Society The Wechsler Memory Scale-Revised (Cantonese version) 1989, Hong Kong Psychological Society, Hong Kong.
22. Hui C.L., Chen E.Y., Kan C., Yip K., Law C., Chiu C.P. Anti-psychotics adherence among out-patients with schizophrenia in Hong Kong. Keio J. Med. 2006, 55(1):9.
23. Hui C.L., Chang W.C., Chan S.K., Lee E.H., Tam W.W., Lai D.C., Wong G.H., Tang J.Y., Li F.W., Leung K.F., McGhee S.M., Sham P.C., Chen E.Y. Early intervention and evaluation for adult-onset psychosis: the JCEP study rationale and design. Early Interv. Psychiatry 2014, 8(3):261-268.
24. Hui C.L., Poon V.W., Kwok V.S., Chang W., Chan S.K., Lee E.H., Chen E.Y. Prevalence and predictors of medication non-adherence among Chinese patients with first-episode psychosis. Pyschiatry Res. 2015, 228:680-687.
25. Jeste S.D., Patterson T.L., Palmer B.W., Dolder C.R., Goldman S., Jeste D.V. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr. Res. 2003, 63(1-2):49-58.
26. Jónsdóttir H., Opjordsmoen S., Birkenaes A., Simonsen C., Engh J., Ringen P., Vaskinn A., Friis S., Sundet K., Andreassen O. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr. Scand. 2013, 127(1):23-33.
27. Kahn R.S., Keefe R.S. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 2013, 70(10):1107-1112.
28. Kampman O., Laippala P., Väänänen J., Koivisto E., Kiviniemi P., Kilkku N., Lehtinen K. Indicators of medication compliance in first-episode psychosis. Psychiatry Res. 2002, 110(1):39-48.
29. Kay S.R., Flszbein A., Opfer L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261.
30. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 2002, 63(10):892-909.
31. Lambert M., Conus P., Eide P., Mass R., Karow A., Moritz S., Golks D., Naber D. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur. Psychiatry 2004, 19(7):415-422.
32. Leckman J.F., Sholomskas D., Thompson D., Belanger A., Weissman M.M. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch. Gen. Psychiatry 1982, 39(8):879-883.
33. Lecomte T., Spidel A., Leclerc C., MacEwan G.W., Greaves C., Bentall R.P. Predictors and profiles of treatment non-adherence and engagement in services problems in early psychosis. Schizophr. Res. 2008, 102(1-3):295-302.
34. Lingjaerde O., Ahlfors U., Bech P., Dencker S., Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 1987, 76(s334):1-100.
35. Malla A.K., Norman R.M., Manchanda R., Ahmed M.R., Scholten D., Harricharan R., Cortese L., Takhar J. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr. Res. 2002, 54(3):231-242.
36. Nelson H.E. A modified card sorting test sensitive to frontal lobe defects. Cortex 1976, 12(4):313-324.
37. Ng C.H., Smith D.J., King J., Ong S., Schweitzer I. Medication attitudes and beliefs in patients with psychotic and affective disorders on maintenance treatment. Hum. Psychopharmacol. 2012, 27(1):57-62.
38. Novak-Grubic V., Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur. Psychiatry 2002, 17(3):148-154.
39. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry 2008, 69(1):106-113.
40. Quach P.L., Mors O., Christensen T.Ø., Krarup G., Jørgensen P., Bertelsen M., Jeppesen P., Petersen L., Thorup A., Nordentoft M. Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Interv. Psychiatry 2009, 3(1):66-74.
41. Richardson M., McCabe R., Priebe S. Are attitudes towards medication adherence associated with medication adherence behaviours among patients with psychosis? A systematic review and meta analysis. Soc. Psychiatry Psychiatr. Epidemiol. 2013, 48(4):649-657.
42. Robinson D.G., Woerner M.G., Alvir J.M.J., Bilder R.M., Hinrichsen G.A., Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 2002, 57(2):209-219.
43. Sendt K.-V., Tracy D.K., Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015, 225(1):14-30.
44. So E., Kam I., Leung C., Chung D., Liu Z., Fong S. The Chinese-bilingual SCID-I/P project: stage 1-reliability for mood disorders and schizophrenia. Hong Kong J. Psychiatry 2003, 13(1):7-18.
45. Thompson K., Kulkarni J., Sergejew A. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. Schizophr. Res. 2000, 42(3):241-247.
46. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70(Suppl. 4):1-46.
47. Yang J., Ko Y.H., Paik J.W., Lee M.S., Han C., Joe S.H., Jung I.K., Jung H.G., Kim S.H. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr. Res. 2012, 134(2-3):226-231.